- Home
- KOSS vs CGTX Comparison
KOSS vs CGTX Comparison
Compare KOSS & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KOSS
- CGTX
- Stock Information
- Founded
- KOSS 1953
- CGTX 2007
- Country
- KOSS United States
- CGTX United States
- Employees
- KOSS N/A
- CGTX N/A
- Industry
- KOSS Consumer Electronics/Appliances
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- KOSS Consumer Staples
- CGTX Health Care
- Exchange
- KOSS Nasdaq
- CGTX Nasdaq
- Market Cap
- KOSS 59.3M
- CGTX 20.5M
- IPO Year
- KOSS N/A
- CGTX 2021
- Fundamental
- Price
- KOSS $5.25
- CGTX $0.34
- Analyst Decision
- KOSS
- CGTX Strong Buy
- Analyst Count
- KOSS 0
- CGTX 5
- Target Price
- KOSS N/A
- CGTX $5.63
- AVG Volume (30 Days)
- KOSS 91.8K
- CGTX 1.3M
- Earning Date
- KOSS 05-08-2025
- CGTX 08-07-2025
- Dividend Yield
- KOSS N/A
- CGTX N/A
- EPS Growth
- KOSS N/A
- CGTX N/A
- EPS
- KOSS N/A
- CGTX N/A
- Revenue
- KOSS $12,433,361.00
- CGTX N/A
- Revenue This Year
- KOSS N/A
- CGTX N/A
- Revenue Next Year
- KOSS N/A
- CGTX N/A
- P/E Ratio
- KOSS N/A
- CGTX N/A
- Revenue Growth
- KOSS N/A
- CGTX N/A
- 52 Week Low
- KOSS $4.00
- CGTX $0.22
- 52 Week High
- KOSS $18.73
- CGTX $2.54
- Technical
- Relative Strength Index (RSI)
- KOSS 50.94
- CGTX 56.40
- Support Level
- KOSS $4.83
- CGTX $0.29
- Resistance Level
- KOSS $5.10
- CGTX $0.34
- Average True Range (ATR)
- KOSS 0.33
- CGTX 0.03
- MACD
- KOSS 0.00
- CGTX 0.01
- Stochastic Oscillator
- KOSS 55.36
- CGTX 85.20
About KOSS Koss Corporation
Koss Corp is engaged in the design, manufacture, and sale of stereo headphones and related accessory products. It operates in the audio/video industry segment of the home entertainment industry. The company markets a line of headphones, wireless Bluetooth headphones, wireless Bluetooth speakers, computer headsets, telecommunications headsets, and active noise-canceling headphones. The majority of the firm's revenue is derived from sales of stereo headphones.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.